We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Momelotinib Yields Long-Term Survival Benefit in Intermediate- or High-Risk Myelofibrosis.
- Authors
Stewart, Patricia
- Abstract
The article discusses that the melotinib, a selective and orally bioavailable inhibitor of Janus kinase (JAK) 1, JAK2, and ACVR1, improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis, according to updated findings from the phase 3 SIMPLIFY-1 and SIMPLIFY-2 clinical trials. It mentions that the Momelotinib was of benefit to patients who received treatment with ruxolitinib and those who had not received a JAK inhibitor.
- Subjects
MYELOFIBROSIS; ACUTE myeloid leukemia
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 3, p20
- ISSN
2164-4403
- Publication type
Article